

**Minnesota Department of Human Services
DUR Board Meeting**

February 8, 2023

Members Present

Daniel Jude, Pharm.D., Karen Pedersen, PharmD., and Ann Philbrick, PharmD.

DHS Staff Present

Mary Beth Reinke, PharmD., DUR Coordinator.

Other Attendants

Ariane Casey, PharmD. Kepro, Cory Chambliss, Kepro, and Alena Mitchell, PharmD, Kepro.

Public Comments: There were no public comments.

Approval of Minutes: Minutes from October 12, 2022 meeting were approved.

Old business:

The updated status of the two recent population-based was 1) Diabetes Management was mailed October 19, 2022 and 2) Overuse of CNS Depressant Controlled Substances criteria was mailed December 15, 2022.

New business:

SUPPORT Act #1 Evaluation

Pre-intervention baseline period, August 6, 2021 to February 2, 2022, consisted of 934 letters to 934 targeted prescribers and 498 distinct targeted patients. A patient could have more than one clinical indicators. In the post-intervention period, there were 443 patients. The overall occurrences on clinical indicators decreased by 46.2%. The 6-month total savings was \$27,432.82 which was \$-10.64 savings per recipient per month or 6-month negative savings of \$-28,291.81. Therefore, clinical edits improved but cost in the post-intervention period was higher.

Psychotropic Drugs in Youth #1 Evaluation

Pre-intervention baseline period, September 5, 2021 to March 4, 2022, consisted of 1,259 letters to 1,259 targeted prescribers and 1,792 distinct targeted patients. A patient could have more than one clinical indicators. In the post-intervention period, there were 1,682 patients. Overall occurrences on clinical indicators decreased by 46.65%. The 6-month total savings was \$27,432.82 which was \$-10.64 savings per recipient per month or 6-month negative savings of \$-27,431.82. There was improvement in clinical edits improved as well as cost savings.

Non-Adherence

The next quarterly mailing, March of 2023, will be non-adherence. Updated counts of potential opportunities for January 2023 were provided. The counts were similar to April 2022. Greatest counts were for Cardiovascular (CV), which includes hypertension, heart failure, and antiplatelets at 226

occurrences. Then, in descending order of occurrence was antipsychotics, hyperlipidemia, and antidepressants with 165, 160, and 154 respectively.

The next DUR Board meeting will be May 10, 2023. The meeting was adjourned.